Therefore, although the main mechanisms responsible for primary or acquired resistance to trastuzumab and to the other HER2-targeted therapies are cancer cell-intrinsic (153), the presence of M2 macrophages and other immunosuppressive cells in the TME significantly impairs the efficacy of HER2-targeting antibodies (164). Here, ERBB2 is linked to cancer.